A Phase 1b Study to Test the Safety, Pharmacokinetics, & Pharmacodynamics of a Novel NLRP3 Inflammasome Inhibitor in Early- Stage Parkinson’s Disease

Time: 9:30 am
day: Day Two

Details:

  • Exploring the drug discovery process: target identification and validation, efficacy, pathway understanding and biomarkers
  • Discussing biomarker and patient status
  • Reviewing latest data and future directions

Speakers: